Melacine: an allogeneic melanoma tumor cell lysate vaccine (Q35194168)

7 August 2017

1 reference

title

Melacine: an allogeneic melanoma tumor cell lysate vaccine (English)

1 reference

7 August 2017

2

Vernon K Sondak

1 reference

7 August 2017

Jeffrey A Sosman

1

1 reference

7 August 2017

publication date

1 June 2003

1 reference

Expert Review of Vaccines

7 August 2017

published in

1 reference

7 August 2017

volume

2

1 reference

7 August 2017

issue

3

1 reference

7 August 2017

page(s)

353-368

1 reference

Malignant melanoma in an HIV-infected man: a case report and literature review

7 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2.3.353

Malignant melanoma in renal-transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2.3.353

Regression of small-cell lung carcinoma in patients with paraneoplastic neuronal antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2.3.353

Anti-Hu antibodies in patients with small-cell lung cancer: association with complete response to therapy and improved survival.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2.3.353

Successful treatment of metastatic renal cell carcinoma with a nonmyeloablative allogeneic peripheral-blood progenitor-cell transplant: evidence for a graft-versus-tumor effect.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2.3.353

A listing of human tumor antigens recognized by T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2.3.353

Cloning of the gene coding for a shared human melanoma antigen recognized by autologous T cells infiltrating into tumor

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2.3.353

A Gene Encoding an Antigen Recognized by Cytolytic T Lymphocytes on a Human Melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2.3.353

A mutated intron sequence codes for an antigenic peptide recognized by cytolytic T lymphocytes on a human melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2.3.353

Active-specific immunotherapy for melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2.3.353

Not so Fas: Re-evaluating the mechanisms of immune privilege and tumor escape

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2.3.353

Characterization of circulating T cells specific for tumor-associated antigens in melanoma patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2.3.353

Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2.3.353

Critical analysis of the current American Joint Committee on Cancer staging system for cutaneous melanoma and proposal of a new staging system

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2.3.353

Interferon alfa therapy for malignant melanoma: a systematic review of randomized controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2.3.353

Identification of a peptide recognized by five melanoma-specific human cytotoxic T cell lines.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2.3.353

Cancer vaccines based on the identification of genes encoding cancer regression antigens

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2.3.353

An expanded peripheral T cell population to a cytotoxic T lymphocyte (CTL)-defined, melanocyte-specific antigen in metastatic melanoma patients impacts on generation of peptide-specific CTLs but does not overcome tumor escape from immune surveillanc

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2.3.353

Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2.3.353

Identification of human cancers deficient in antigen processing

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2.3.353

Loss of functional beta 2-microglobulin in metastatic melanomas from five patients receiving immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2.3.353

Regulatory T cells in autoimmmunity*.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2.3.353

Interaction of heat shock proteins with peptides and antigen presenting cells: chaperoning of the innate and adaptive immune responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2.3.353

Surgical adjuvant active specific immunotherapy for patients with stage III melanoma: the final analysis of data from a phase III, randomized, double-blind, multicenter vaccinia melanoma oncolysate trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2.3.353

Quality of life in patients with metastatic renal cell carcinoma participating in a phase I trial of an autologous tumor-derived vaccine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2.3.353

Unique glycoprotein-proteoglycan complex defined by monoclonal antibody on human melanoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2.3.353

21 January 2018

Identifiers

DOI

10.1586/14760584.2.3.353

1 reference

7 August 2017

1 reference